Publications by authors named "R Buzzetti"
Background: Glucagon-like peptide 1 receptor agonists (RA) are novel agents used in the management of type 2 diabetes (T2D) and obesity. Although highly effective, the response to treatment may vary significantly among patients.
Objective: This perspective review aims to summarise the current knowledge about markers of poor or good response to GLP-1 RA, highlighting the possibility of tailoring treatment strategies and reducing costs associated with T2D and obesity treatment.
Type 2 diabetes in children and adolescents: Challenges for treatment and potential solutions.
Diabetes Res Clin Pract
November 2024
Article Synopsis
- The prevalence of type 2 diabetes mellitus (T2DM) in children and adolescents is increasing, largely due to rising childhood obesity rates, making it a significant public health issue worldwide.
- Treating youth-onset T2DM is challenging due to limited treatment options, reliance on adult-based guidelines, and difficulties in conducting pediatric studies.
- Recent treatment guidelines from organizations like ADA, NICE UK, and ISPAD aim to address these challenges, explore unique aspects of youth-onset T2DM, and identify treatment gaps while promoting further research for better outcomes.
Aims: To assess whether impaired vestibular perception of self-motion is a risk factor for unsteadiness and falls in elderly patients with type 2 diabetes (T2D).
Materials And Methods: 113 participants (65-75 years old) with T2D underwent tests of roll and pitch discrimination, postural stability (Berg Balance Scale, Modified Romberg Test, and quantitative posturography), clinical examination and blood chemistry analyses. Falls 1-year after enrolment were self-reported.
Background: Recovery from acute COVID-19 may be slow and incomplete: cases of Post-Acute Sequelae of COVID (PASC) are counted in millions, worldwide. We aimed to explore if and how the pre-existing Socio-economic-status (SES) influences such recovery.
Methods: We analyzed a database of 1536 consecutive patients from the first wave of COVID-19 in Italy (February-September 2020), previously admitted to our referral hospital, and followed-up in a dedicated multidisciplinary intervention.
Article Synopsis
- Diabetic nephropathy is a major cause of kidney disease in developed countries, and this study aimed to compare the effects of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) on kidney function in patients with type 2 diabetes mellitus.
- A total of 478 patients were analyzed, and results showed that the reduction in estimated glomerular filtration rate (eGFR) after 24 months was similar for both treatments, with no significant differences in weight loss or treatment discontinuation.
- The findings suggest that both classes of medication have similar effects on kidney function over time, indicating their potential for managing diabetic nephropathy effectively.